Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April A N Rose

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Nuclear Medicine Communications|May 10, 2024
A phase 2, single-arm trial evaluating 131 I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancerRichard F Liu, Cristiano Ferrario, Parvaneh Fallah, et al.
Plos One|August 17, 2010
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic propertiesApril A N Rose, Matthew G Annis, Zhifeng Dong, et al.
The American Journal of Pathology|April 13, 2010
Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cellsMélanie Demers, April A N Rose, Andrée-Anne Grosset, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
JCO Oncology Practice|December 8, 2020
Increasing Referrals of Patients With Gastrointestinal Cancer to a Cancer Rehabilitation Program: A Quality Improvement InitiativeMichelle B Nadler, April A N Rose, Rebecca Prince, et al.
Clinical Breast Cancer|May 3, 2025
High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancerSoumaya Labidi, Nasser Mulla, Islam E Elkholi, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single CentreAnna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, et al.
Breast Cancer Research : BCR|April 18, 2015
Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastasesSébastien Tabariès, Véronique Ouellet, Brian E Hsu, et al.
Cancers|July 29, 2023
Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to ImmunotherapyMaysa Vilbert, Erica C Koch, April A N Rose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancerJohanna Bendell, Mansoor Saleh, April A N Rose, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Nuclear Medicine Communications|May 10, 2024
A phase 2, single-arm trial evaluating 131 I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancerRichard F Liu, Cristiano Ferrario, Parvaneh Fallah, et al.
Plos One|August 17, 2010
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic propertiesApril A N Rose, Matthew G Annis, Zhifeng Dong, et al.
The American Journal of Pathology|April 13, 2010
Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cellsMélanie Demers, April A N Rose, Andrée-Anne Grosset, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
JCO Oncology Practice|December 8, 2020
Increasing Referrals of Patients With Gastrointestinal Cancer to a Cancer Rehabilitation Program: A Quality Improvement InitiativeMichelle B Nadler, April A N Rose, Rebecca Prince, et al.
Clinical Breast Cancer|May 3, 2025
High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancerSoumaya Labidi, Nasser Mulla, Islam E Elkholi, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single CentreAnna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, et al.
Breast Cancer Research : BCR|April 18, 2015
Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastasesSébastien Tabariès, Véronique Ouellet, Brian E Hsu, et al.
Cancers|July 29, 2023
Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to ImmunotherapyMaysa Vilbert, Erica C Koch, April A N Rose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancerJohanna Bendell, Mansoor Saleh, April A N Rose, et al.
Pageof 5